Holger Reithinger is General Partner and heads the Munich Office of venture capital firm Forbion. He is also member of the investment committee of the Hightech-Gründer Fonds, Germany’s biggest early-stage and seed investor. Prior to joining Forbion, he was Partner at Global Life Science Ventures and Director at Germany’s healthcare practice of 3i and Investment Manager at Technologieholding VC. Dr. Reithinger studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. He holds a PhD in Biochemistry from the Max-Planck-Institute of Biophysics, which he obtained under the supervision of Prof. Dr. Arne Skerra in the department of Prof. Dr. Hartmut Michel.